Conjugate Vaccines Market Size, Share & Industry Trends Analysis 2024-32
The Reports and Insights, a leading market research company, has recently releases report titled “Conjugate Vaccines Market: Global Industry Trends, ...
Pharmaceutical Technology13d
Ascendis Pharma gets grant for controlled-release parathyroid hormone conjugate for medical treatment
Discover the groundbreaking patent by Ascendis Pharma AS for a controlled-release PTH compound, revolutionizing treatment for various conditions. Learn more about the innovative formula and its ...
Daily7h
Biological E Gets CDSCO Panel Nod for Continued Safety study of 14-valent pneumococcal polysaccharide conjugate vaccine
A Phase IV multicentre follow-up study to assess the continued safety of Biological E’s 14-valent pneumococcal polysaccharide conjugate vaccine in subjects, who received 3-dose (3+0) primary PCV ...
FiercePharma1d
ADC Therapeutics touts early Zynlonta results in marginal zone lymphoma, raises $105M through share sale
In a flurry of updates Monday, ADC Therapeutics revealed that it's selling $105 million in new shares while also touting results for antibody-drug conjugate Zynlonta from a small investigator-initi | ...
JD Supra7d
Cancer Drugs: Strategies For Patenting Antibody-Drug Conjugate Inventions
Antibody-drug conjugate (ADC) is a promising class of cancer treatments with accelerating U.S. Food and Drug Administration (FDA) approval and rapidly growing market size as discussed in previous ...
BioSpace7h
ADC Therapeutics Posts Early Phase II Lymphoma Data for Zynlonta as Revenue Drops 5.8%
ADC Therapeutics is positioning Zynlonta for a label expansion with new Phase II data showing that the treatment can elicit high rates of complete response in patients with relapsed or refractory ...
BioAtla Says FDA Clears IND Application For BA3361 For The Treatment Of Multiple Tumors
Biotechnology company BioAtla, Inc. (BCAB) announced Monday that the U.S. Food and Drug Administration (FDA) has cleared its ...
FierceBiotech8d
On doorstep of approval, Merck compares V116 pneumococcal vaccine to 1983 warhorse Pneumovax 23
In the STRIDE-10 study, Merck’s V116—which is a 21-valent conjugate vaccine designed for adults—stacked up favorably against ...
Monthly Prescribing Reference7d
STRIDE-10 Results Support Merck’s 21-Valent Pneumococcal Conjugate Vaccine
Positive findings were announced from a phase 3 trial comparing Merck’s investigational 21-valent pneumococcal conjugate vaccine, V116, to pneumococcal 23-valent polyvalent vaccine (PPSV23) in ...
The Pharma Letter7d
First adult-targeted pneumococcal conjugate vaccine moves closer
US pharma giant Merck & Co (NYSE: MRK) has announced results from STRIDE-10, a Phase III trial of V116, the company’s investigational, adult-specific 21-valent pneumococcal conjugate vaccine (PCV), ...
Business Insider12h
Corbus Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
Key Corporate and Program Updates: CRB-701: CRB-701 (SYS6002) is a next-generation antibody drug conjugate targeting Nectin-4 that contains a site-specific, cleavable linker and a homogenous drug ...
BE’s 14-Valent Pneumococcal Conjugate Vaccine: Phase III trials prove ‘safety’
The phase III clinical trials of Biological E’s (BE)’s 14-Valent Pneumococcal Conjugate Vaccine (PCV), Pneubevax14 (BE-PCV-14 ...